Therefore, future studies must consider important tumor-specific genetic, epigenetic, and transcriptomic alterations before and after therapy, such as MEN1/DAXX/ATRX mutations, ARX expression, and their corresponding phenotypic manifestations (i.e., ALT), as defining characteristics that may impact tumor recurrence and the survival of patients with PNETs. Here, DAXX is linked to neoplasm.